Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29254943 | 0.87 | CA12 (0.49) | TP53ALOX12ADORA2AADORA1ALDH1A1 | |
| SCHEMBL1999421 | 0.86 | SMN1; SMN2 (0.48) | TP53ALOX12ADORA2AADORA1PDE4D | |
| SCHEMBL22768993 | 0.86 | PDE4D (0.53) | TP53ALOX12ADORA2AADORA1PDE4D | |
| SCHEMBL12442229 | 0.86 | NPC1 (0.52) | ALDH1A1NPC1RAB9AMAPTGABRA2 | |
| SCHEMBL25170232 | 0.85 | NPC1 (0.48) | TP53ALOX12ADORA2AADORA1PDE4D | |
| SCHEMBL15019791 | 0.85 | ALDH1A1 (0.53) | TP53ALOX12ADORA1ALDH1A1HPGD | |
| SCHEMBL25415963 | 0.81 | FAAH (0.53) | TP53ALOX12ADORA2AADORA1ALDH1A1 | |
| SCHEMBL17291879 | 0.80 | MAPT (0.58) | TP53ALOX12ALDH1A1GAANPC1 | |
| SCHEMBL28728715 | 0.78 | NPC1 (0.62) | TP53ALOX12ADORA2AADORA1PDE4D | |
| SCHEMBL28577491 | 0.78 | CYP1A2 (0.41) | TP53ALOX12ADORA2AADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2022-04-28 | — | — | US | disclosed |
| US-11059825-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059825-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200095251-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10287292-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10287292-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-2925745-A1 | CXCR7 ANTAGONISTS | ChemoCentryx, Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| US-20140154179-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2014085490-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014085490-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20140154179-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140154179-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8586707-B2 | Stapled peptides and method of synthesis | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2334317-A2 | STAPLED PEPTIDES AND METHOD OF SYNTHESIS | The Research Foundation Of State University Of New York (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100093086-A1 | Stapled Peptides and Method of Synthesis | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-04-15 | — | — | US | disclosed |
| WO-2010033617-A2 | STAPLED PEPTIDES AND METHOD OF SYNTHESIS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287292-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | TP53 3953/4885ALOX12 1690/4885ADORA2A 302/4885 |
| US-20100093086-A1 | Stapled Peptides and Method of Synthesis | VIP, HM13, NGLY1 | TP53 341/4885ALOX12 3438/4885ADORA2A 4792/4885 |
| US-11059825-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | TP53 3953/4885ALOX12 1690/4885ADORA2A 302/4885 |
| US-11834452-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | TP53 3953/4885ALOX12 1690/4885ADORA2A 302/4885 |
| US-20200095251-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | TP53 3953/4885ALOX12 1690/4885ADORA2A 302/4885 |
| US-20140154179-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | TP53 3953/4885ALOX12 1690/4885ADORA2A 302/4885 |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | TP53 3953/4885ALOX12 1690/4885ADORA2A 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.